NCT02567253View on ClinicalTrials.gov

Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

August 25, 2021

Conditions
Ovarian CancerPrimary Peritoneal Cancer
Interventions
PROCEDURE

Cytoreductive surgery

Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer

DRUG

IPEC with Cisplatin (75mg/m²)

Intraperitoneal normotherm (37°C) administration of Cisplatin (75mg/m²) , during 90min

DRUG

IPEC with Cisplatin (100mg/m²)

Intraperitoneal normotherm (37°C) administration of Cisplatin (100mg/m²), during 90min

DRUG

Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)

Intraperitoneal hypertherm (41°C) administration of Cisplatin (75mg/m²), during 90min

DRUG

HIPEC with Cisplatin (100mg/m²)

Intraperitoneal hypertherm (41°C) administration of Cisplatin (100mg/m²), during 90min

Trial Locations (1)

9000

UZ Ghent, Ghent

All Listed Sponsors
lead

University Hospital, Ghent

OTHER

NCT02567253 - Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer | Biotech Hunter | Biotech Hunter